© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 6, 484-486,
March 19, 2003
© 2003 Oxford University Press
BRIEF COMMUNICATION |
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Affiliations of authors: G. Singer, R. Oldt III, B. G. Wang (Department of Pathology), Y. Cohen, D. Sidransky (Head and Neck Cancer Research Division), R. J. Kurman, I.-M. Shih (Departments of Pathology and Gynecology and Obstetrics), The Johns Hopkins University School of Medicine, Baltimore, MD.
Correspondence to: Ie-Ming Shih, M.D., Ph.D., Department of Pathology, The Johns Hopkins University School of Medicine, 418 N. Bond St., B-315, Baltimore, MD 21231 (e-mail: ishih{at}jhmi.edu).
ABSTRACT
Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68%) invasive micropapillary serous carcinomas (MPSCs; low-grade tumors) and in 31 of 51 (61%) serous borderline tumors (precursor lesions to invasive MPSCs). None of the tumors contained a mutation in both BRAF and KRAS. In contrast, none of the 72 conventional aggressive high-grade serous carcinomas analyzed contained the BRAF codon 599 mutation or either of the two KRAS mutations. The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R Seth, S Crook, S Ibrahem, W Fadhil, D Jackson, and M Ilyas Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer Gut, September 1, 2009; 58(9): 1234 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-K. Yoon, H.-P. Kim, S.-W. Han, H.-S. Hur, D. Y. Oh, S.-A. Im, Y.-J. Bang, and T.-Y. Kim Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells Mol. Cancer Ther., September 1, 2009; 8(9): 2526 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Grimley, R. K. Matsuno, P. S. Rosenberg, D. E. Henson, A. M. Schwartz, and W. F. Anderson Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas Cancer Epidemiol. Biomarkers Prev., August 1, 2009; 18(8): 2256 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas Cancer Res., May 1, 2009; 69(9): 4036 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-T. Kuo, T.-L. Mao, S. Jones, E. Veras, A. Ayhan, T.-L. Wang, R. Glas, D. Slamon, V. E. Velculescu, R. J. Kuman, et al. Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma Am. J. Pathol., May 1, 2009; 174(5): 1597 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.-C. Sheu, C.-H. Hua, L. Wan, Y.-J. Lin, M.-T. Lai, H.-C. Tseng, N. Jinawath, M.-H. Tsai, N.-W. Chang, C.-F. Lin, et al. Functional Genomic Analysis Identified Epidermal Growth Factor Receptor Activation as the Most Common Genetic Event in Oral Squamous Cell Carcinoma Cancer Res., March 15, 2009; 69(6): 2568 - 2576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Olsen, A. C Green, C. M Nagle, S. J Jordan, D. C Whiteman, C. J Bain, P. M Webb, and on behalf of the Australian Cancer Study Group (Ov Epithelial ovarian cancer: testing the 'androgens hypothesis' Endocr. Relat. Cancer, December 1, 2008; 15(4): 1061 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zang, J. Gong, L. Luo, J. Zhou, X. Xiang, W. Huang, Q. Huang, X. Luo, M. Olbrot, Y. Peng, et al. Characterization of Ser338 Phosphorylation for Raf-1 Activation J. Biol. Chem., November 14, 2008; 283(46): 31429 - 31437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Levanon, C. Crum, and R. Drapkin New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact J. Clin. Oncol., November 10, 2008; 26(32): 5284 - 5293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Anglesio, J. M. Arnold, J. George, A. V. Tinker, R. Tothill, N. Waddell, L. Simms, B. Locandro, S. Fereday, N. Traficante, et al. Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors Mol. Cancer Res., November 1, 2008; 6(11): 1678 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dal Lago, V. D'Hondt, and A. Awada Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors Oncologist, August 1, 2008; 13(8): 845 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schildkraut, P. G. Moorman, A. E. Bland, S. Halabi, B. Calingaert, R. Whitaker, P. S. Lee, T. Elkins-Williams, R. C. Bentley, J. R. Marks, et al. Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 585 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Spittle, M. R. Ward, K. L. Nathanson, P. A. Gimotty, E. Rappaport, M. S. Brose, A. Medina, R. Letrero, M. Herlyn, and R. H. Edwards Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma J. Mol. Diagn., September 1, 2007; 9(4): 464 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rahmani, E. M. Davis, T. R. Crabtree, J. R. Habibi, T. K. Nguyen, P. Dent, and S. Grant The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress Mol. Cell. Biol., August 1, 2007; 27(15): 5499 - 5513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Henderson, M. J. Fredrick, and G. L. Clayman Differential Responses of Human Papillary Thyroid Cancer Cell Lines Carrying the RET/PTC1 Rearrangement or a BRAF Mutation to MEK1/2 Inhibitors Arch Otolaryngol Head Neck Surg, August 1, 2007; 133(8): 810 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Davies, A. Logie, J. S. McKay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, and P. D. Smith AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol. Cancer Ther., August 1, 2007; 6(8): 2209 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yancovitz, J. Yoon, M. Mikhail, W. Gai, R. L. Shapiro, R. S. Berman, A. C. Pavlick, P. B. Chapman, I. Osman, and D. Polsky Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma J. Mol. Diagn., April 1, 2007; 9(2): 178 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stadlmann, U. Gueth, E. Wight, L. A Kunz-Schughart, A. Hartmann, and G. Singer Expression of peroxisome proliferator activated receptor {gamma} and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma J. Clin. Pathol., March 1, 2007; 60(3): 307 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-J. Kim, H. C. Kang, S. G. Jang, S.-A Ahn, H.-J. Yoon, and J.-G. Park Development and Applications of a BRAF Oligonucleotide Microarray J. Mol. Diagn., February 1, 2007; 9(1): 55 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Young, F. C. Mei, D. G. Rosen, G. Yang, N. Li, J. Liu, and X. Cheng Up-regulation of Tumor Susceptibility Gene 101 Protein in Ovarian Carcinomas Revealed by Proteomics Analyses Mol. Cell. Proteomics, February 1, 2007; 6(2): 294 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Murphy, S. Makonnen, W. Lassoued, M. D. Feldman, C. Carter, and W. M.F. Lee Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006) Am. J. Pathol., November 1, 2006; 169(5): 1875 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yang, D. G. Rosen, Z. Zhang, R. C. Bast Jr., G. B. Mills, J. A. Colacino, I. Mercado-Uribe, and J. Liu The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis PNAS, October 31, 2006; 103(44): 16472 - 16477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Petti, A. Molla, C. Vegetti, S. Ferrone, A. Anichini, and M. Sensi Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. Cancer Res., July 1, 2006; 66(13): 6503 - 6511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Teraishi, W. Guo, L. Zhang, F. Dong, J. J. Davis, T. Sasazuki, S. Shirasawa, J. Liu, and B. Fang Activation of Sterile20-Like Kinase 1 in Proteasome Inhibitor Bortezomib-Induced Apoptosis in Oncogenic K-ras-Transformed Cells. Cancer Res., June 15, 2006; 66(12): 6072 - 6079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. McPhillips, P. Mullen, K. G. MacLeod, J. M. Sewell, B. P. Monia, D. A. Cameron, J. F. Smyth, and S. P. Langdon Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells Carcinogenesis, April 1, 2006; 27(4): 729 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-J. Kim, H. C. Kang, S.-G. Jang, K. Kim, S.-A Ahn, H.-J. Yoon, S. N. Yoon, and J.-G. Park Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations Carcinogenesis, March 1, 2006; 27(3): 392 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Sapio, D. Posca, G. Troncone, G. Pettinato, L. Palombini, G. Rossi, G. Fenzi, and M. Vitale Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA) Eur. J. Endocrinol., February 1, 2006; 154(2): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Yen, C.-Y. Hsu, T.-L. Mao, T-C. Wu, R. Roden, T.-L. Wang, and I.-M. Shih Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma Clin. Cancer Res., February 1, 2006; 12(3): 827 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mercer, S. Giblett, S. Green, D. Lloyd, S. DaRocha Dias, M. Plumb, R. Marais, and C. Pritchard Expression of Endogenous Oncogenic V600EB-raf Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts Cancer Res., December 15, 2005; 65(24): 11493 - 11500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bonome, J.-Y. Lee, D.-C. Park, M. Radonovich, C. Pise-Masison, J. Brady, G. J. Gardner, K. Hao, W. H. Wong, J. C. Barrett, et al. Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary Cancer Res., November 15, 2005; 65(22): 10602 - 10612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahmani, E. M. Davis, C. Bauer, P. Dent, and S. Grant Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation J. Biol. Chem., October 21, 2005; 280(42): 35217 - 35227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L.G. Sieben, J. Oosting, A. M. Flanagan, J. Prat, G. M.J.M. Roemen, S. M. Kolkman-Uljee, R. van Eijk, C. J. Cornelisse, G. J. Fleuren, and M. van Engeland Differential Gene Expression in Ovarian Tumors Reveals Dusp 4 and Serpina 5 As Key Regulators for Benign Behavior of Serous Borderline Tumors J. Clin. Oncol., October 10, 2005; 23(29): 7257 - 7264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Beeram, A. Patnaik, and E. K. Rowinsky Raf: A Strategic Target for Therapeutic Development Against Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kobel, G. Pohl, W. D. Schmitt, S. Hauptmann, T.-L. Wang, and I.-M. Shih Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor Am. J. Pathol., September 1, 2005; 167(3): 879 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Marquez, K. A. Baggerly, A. P. Patterson, J. Liu, R. Broaddus, M. Frumovitz, E. N. Atkinson, D. I. Smith, L. Hartmann, D. Fishman, et al. Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon Clin. Cancer Res., September 1, 2005; 11(17): 6116 - 6126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Adjei and M. Hidalgo Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy J. Clin. Oncol., August 10, 2005; 23(23): 5386 - 5403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Xing BRAF mutation in thyroid cancer Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pohl, C.-L. Ho, R. J. Kurman, R. Bristow, T.-L. Wang, and I.-M. Shih Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations Cancer Res., March 1, 2005; 65(5): 1994 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Chen, G. Pohl, T.-L. Wang, P. J. Morin, B. Risberg, G. B. Kristensen, A. Yu, B. Davidson, and I.-M. Shih Apolipoprotein E Is Required for Cell Proliferation and Survival in Ovarian Cancer Cancer Res., January 1, 2005; 65(1): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Penson, D. Sahani, and D. A. Bell Case 37-2004 - A 52-Year-Old Woman with Postmenopausal Bleeding and a Cystic Ovarian Mass N. Engl. J. Med., December 9, 2004; 351(24): 2531 - 2538. [Full Text] [PDF]
|
|
|
|
|
|
C.-L. Ho, R. J. Kurman, R. Dehari, T.-L. Wang, and I.-M. Shih Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors Cancer Res., October 1, 2004; 64(19): 6915 - 6918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Steinmetz, H. A. Wagoner, P. Zeng, J. R. Hammond, T. S. Hannon, J. L. Meyers, and O. H. Pescovitz Mechanisms Regulating the Constitutive Activation of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway in Ovarian Cancer and the Effect of Ribonucleic Acid Interference for ERK1/2 on Cancer Cell Proliferation Mol. Endocrinol., October 1, 2004; 18(10): 2570 - 2582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Hsu, R. Bristow, M. S. Cha, B. G. Wang, C.-L. Ho, R. J. Kurman, T.-L. Wang, and I.-M. Shih Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas Clin. Cancer Res., October 1, 2004; 10(19): 6432 - 6436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lima, V. Trovisco, P. Soares, V. Maximo, J. Magalhaes, G. Salvatore, M. Santoro, T. Bogdanova, M. Tronko, A. Abrosimov, et al. BRAF Mutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4267 - 4271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Kambara, L A Simms, V L J Whitehall, K J Spring, C V A Wynter, M D Walsh, M A Barker, S Arnold, A McGivern, N Matsubara, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum Gut, August 1, 2004; 53(8): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Young, F. C. Mei, G. Yang, J. A. Thompson-Lanza, J. Liu, and X. Cheng Activation of Antioxidant Pathways in Ras-Mediated Oncogenic Transformation of Human Surface Ovarian Epithelial Cells Revealed by Functional Proteomics and Mass Spectrometry Cancer Res., July 1, 2004; 64(13): 4577 - 4584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikenoue, Y. Hikiba, F. Kanai, J. Aragaki, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, et al. Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor {kappa}B Pathway and Cellular Transformation Cancer Res., May 15, 2004; 64(10): 3428 - 3435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cohen, E. Rosenbaum, S. Begum, D. Goldenberg, C. Esche, O. Lavie, D. Sidransky, and W. H. Westra Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites Clin. Cancer Res., May 15, 2004; 10(10): 3444 - 3447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Puxeddu, S. Moretti, R. Elisei, C. Romei, R. Pascucci, M. Martinelli, C. Marino, N. Avenia, E. D. Rossi, G. Fadda, et al. BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2414 - 2420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-M. Shih and R. J. Kurman Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis Am. J. Pathol., May 1, 2004; 164(5): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hogg and M. Friedlander Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk J. Clin. Oncol., April 1, 2004; 22(7): 1315 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H Edwards, M R Ward, H Wu, C A Medina, M S Brose, P Volpe, S Nussen-Lee, H M Haupt, A M Martin, M Herlyn, et al. Absence of BRAF mutations in UV-protected mucosal melanomas J. Med. Genet., April 1, 2004; 41(4): 270 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, G. Yang, J. A. Thompson-Lanza, A. Glassman, K. Hayes, A. Patterson, R. T. Marquez, N. Auersperg, Y. Yu, W. C. Hahn, et al. A Genetically Defined Model for Human Ovarian Cancer Cancer Res., March 1, 2004; 64(5): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Xing, Y. Cohen, E. Mambo, G. Tallini, R. Udelsman, P. W. Ladenson, and D. Sidransky Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis Cancer Res., March 1, 2004; 64(5): 1664 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression Clin. Cancer Res., December 15, 2003; 9(17): 6483 - 6488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikenoue, Y. Hikiba, F. Kanai, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, T. Kawakami, et al. Functional Analysis of Mutations within the Kinase Activation Segment of B-Raf in Human Colorectal Tumors Cancer Res., December 1, 2003; 63(23): 8132 - 8137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Ulku, R. Schafer, and C. J. Der Essential Role of Raf in Ras Transformation and Deregulation of Matrix Metalloproteinase Expression in Ovarian Epithelial Cells Mol. Cancer Res., December 1, 2003; 1(14): 1077 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Calhoun, J. B. Jones, R. Ashfaq, V. Adsay, S. J. Baker, V. Valentine, P. M. Hempen, W. Hilgers, C. J. Yeo, R. H. Hruban, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer: Potential Therapeutic Targets Am. J. Pathol., October 1, 2003; 163(4): 1255 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cruz III, B. P. Rubin, D. Wilson, A. Town, A. Schroeder, A. Haley, T. Bainbridge, M. C. Heinrich, and C. L. Corless Absence of BRAF and NRAS Mutations in Uveal Melanoma Cancer Res., September 15, 2003; 63(18): 5761 - 5766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kumar, S. Angelini, K. Czene, I. Sauroja, M. Hahka-Kemppinen, S. Pyrhonen, and K. Hemminki BRAF Mutations in Metastatic Melanoma: A Possible Association with Clinical Outcome Clin. Cancer Res., August 1, 2003; 9(9): 3362 - 3368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Wang, H.-Y. Huang, Y.-C. Chen, R. E. Bristow, K. Kassauei, C.-C. Cheng, R. Roden, L. J. Sokoll, D. W. Chan, and I.-M. Shih Increased Plasma DNA Integrity in Cancer Patients Cancer Res., July 15, 2003; 63(14): 3966 - 3968. [Abstract] [Full Text] [PDF]
|
|